Ontario Clinical Practice Guidelines for Antimicrobial and Immunomodulatory Therapy in Adult Patients with COVID-19

**Chloroquine or hydroxychloroquine** is not recommended outside of approved clinical trials or where other indications would justify its use

**Lopinavir/ritonavir** is not recommended outside of approved clinical trials

**Remdesivir** is not recommended outside of approved clinical trials (currently unavailable in Canada)

**Ceftriaxone 1 g IV q24h x 5 days** is recommended if there is concern for bacterial co-infection (Alternative for severe beta-lactam hypersensitivity: levofloxacin 750 mg IV or moxifloxacin 400 mg IV q24h x 5 days)

**Add azithromycin 500 mg IV q24h x 5 days to ceftriaxone empiric therapy if Legionella infection is suspected (azithromycin is not needed if empiric therapy is levofloxacin or moxifloxacin)**

*De-escalate on the basis of microbiology results and clinical judgment*

**Corticosteroids** should not be offered outside of approved clinical trials unless there are other indications for its use

**Tocilizumab** should not be offered routinely outside of approved clinical trials; may be considered on an individual basis in patients with cytokine storm (with expert consultation)

**COVID-19 convalescent plasma** is currently unavailable in Canada in critically ill patients and is unavailable outside of clinical trials

**Corticosteroids** should not be offered outside of approved clinical trials unless there are other indications for its use

**Tocilizumab** is not recommended outside of approved clinical trials

**COVID-19 convalescent plasma** is not recommended outside of approved clinical trials (unavailable outside of clinical trials)

**Vitamin C (ascorbic acid)** is not recommended outside of approved clinical trials

**Vitamin C (ascorbic acid)** is not recommended outside of approved clinical trials

---

**Numerous therapies have shown a theoretical or mechanistic basis to be beneficial in the management against COVID-19, however clinical data supporting the use of these therapies are lacking. Refer to the complete guidelines for further discussion.**

**This document is dynamic and will be updated as changes to recommendations occur. The complete and most up-to-date version of the guidelines is available at www.antimicrobialstewardship.com/covid-19. Last updated on April 20, 2020.**